Drug Trial Radar · NCT01097044
Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Last checked: Nov 20, 2026Latest source record: Oct 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Apr 2010
Primary completion
Apr 2011
Study completion Apr 2011
Sponsor
- Lead sponsor
- Clinuvel Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized placebo-controlled study to be conducted in two parallel study arms for a six month period (three doses). Approximately 10 eligible patients per center will be enrolled and will receive afamelanotide (16 mg implants) or placebo according to the following dosing regimen: * Group A will be administered afamelanotide implants on Days 0, 60 and 120 * Group B will be administered placebo implants on Days 0, 60 and 120 To determine eligibility for study inclusion, patients will undergo a screening evaluation 7 to 14 days prior to the administration of the first dose. The number and severity of phototoxic reactions will be determined Days 60, 120, and 180. Quality of life will be measured using the EPP specific questionnaire (EPP-QoL) every 60 days and the DLQI questionnaire every 7 days, beginning at Day 0 until Day 180. Participants will visit the clinic on Days 60, 120 and 180 for assessments of adverse events.
Conditions
- Erythropoietic Protoporphyria
Interventions
AfamelanotideDrug
One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
PlaceboDrug
One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time in Direct Sunlight Between 10:00-15:00 on Pain-free DaysTime frame: Daily for 6 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
University of California, San Francisco
San Francisco, California
Mt. Sinai
New York, New York
Carolina's Medical Center Cannon Research
Charlotte, North Carolina
University of Texas
Galveston, Texas
University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.